Summit Therapeutics (SMMT) Equity Ratio (2019 - 2025)
Summit Therapeutics (SMMT) has disclosed Equity Ratio for 7 consecutive years, with 0.73 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Equity Ratio fell 15.65% year-over-year to 0.73, compared with a TTM value of 0.73 through Sep 2025, down 15.65%, and an annual FY2024 reading of 0.89, up 133.15% over the prior year.
- Equity Ratio was 0.73 for Q3 2025 at Summit Therapeutics, down from 0.8 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.9 in Q1 2025 and bottomed at 0.19 in Q4 2022.
- Average Equity Ratio over 5 years is 0.62, with a median of 0.57 recorded in 2024.
- The sharpest move saw Equity Ratio plummeted 74.04% in 2022, then soared 258.72% in 2025.
- Year by year, Equity Ratio stood at 0.73 in 2021, then tumbled by 74.04% to 0.19 in 2022, then surged by 100.75% to 0.38 in 2023, then soared by 133.15% to 0.89 in 2024, then fell by 17.7% to 0.73 in 2025.
- Business Quant data shows Equity Ratio for SMMT at 0.73 in Q3 2025, 0.8 in Q2 2025, and 0.9 in Q1 2025.